Schering-Plough has reported to the FDA that the company has completed all of the 212 significant steps and 30 validation actions required by Dec. 31, 2005, under its consent decree. “The timely completion of our cGMP Work Plan and Validation Certification Program represents another significant milestone as we work to build the New Schering-Plough,” said Fred Hassan, S-P’s chairman and chief executive officer. “Many Schering-Plough colleagues worked tirelessly and with a ...